Kymera Therapeutics develops oral medicines for immune and inflammatory diseases using targeted protein degradation. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). In the past 30 days there were 3 dark pool prints.
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 30 | Truist Securities | Target raised | Buy | |
| Oct 30 | RBC Capital | Target raised | Hold | |
| Oct 29 | BTIG | Target raised | Buy | |
| Oct 27 | Morgan Stanley | Maintained | Buy | |
| Oct 9 | Raymond James | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in KYMR in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYMR is in one of them and how their past KYMR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KYMR in an article yet. Here's the latest on the wider market.
About Kymera Therapeutics
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that develops oral medicines. It uses targeted protein degradation, a method that taps into the body's own cell recycling system to remove proteins that cause disease. Its main focus is immunology, with programs aimed at conditions such as atopic dermatitis and asthma, which are often treated with injections. Its medicines are still in clinical testing and are intended for patients with these conditions.
- Headquarters
- Watertown, MA
- Website
- kymeratx.com ↗